Russian scientists have developed an mRNA cancer vaccine, named Enteromix, which is now ready for clinical trials. The announcement came from the Federal Medical and Biological Agency (FMBD). According to its head, Veronica Skvortsov, the vaccine has successfully passed pre-clinical trials, demonstrating both safety and high effectiveness. In experimental stages, the vaccine has shown significant results in shrinking tumours and slowing their growth. The treatment is reportedly effective for brain, skin, and rectal cancers. A key feature of the new vaccine is that it will be customized for each patient, tailored to their individual RNA. The vaccine is considered a potential medical breakthrough in the health sector